Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1.
Traumatic brain injury remains a major cause of death and disability; it is estimated that annually 10 million people are affected. Preclinical studies have shown the potential therapeutic value of stem cell therapies. Neuroprotective as well as regenerative properties of stem cells have been suggested to be the mechanism of action in preclinical studies. However, up to now stem cell therapy has not been studied extensively in clinical trials. This article summarizes the current experimental evidence and points out hurdles for clinical application. Focusing on a cell therapy in the acute stage of head injury, the potential of encapsulated cell biodelivery as a novel cell-therapeutic approach will also be discussed.
International Neuroscience Institute, Hannover, Germany. annaheile@t-online.de
Anna
A
Heile
Thomas
T
Brinker
D000818:Animals; D001930:Brain Injuries / Q000628:therapy*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage*; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D014162:Transfection / Q000379:methods; D057170:Translational Research, Biomedical
D052216:Glucagon-Like Peptide 1